The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis
- 18 February 2018
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 52 (7) , 613-622
Abstract
Background: Previous meta-analyses suggest that users of proton pump inhibitors (PPIs) have a higher risk of developing enteric infections compared with nonusers. These previous meta-analyses have considerable heterogeneity, and it is not clear whether the effect of PPIs is different for different types of microorganisms. Objective: The aim of this study is to update previous meta-analyses, concentrating on enteric infection in community settings and exploring potential sources of heterogeneity. Methods: A systematic search was conducted on electronic databases (all available years until November 2017). PubMed, EMBASE, Cochrane, and Web of Science were searched using specific keywords related to PPI therapy and community-acquired enteric infection. Eligible studies were selected based on prespecified criteria. Results: A total of 9 observational studies evaluating community-acquired enteric infection were eligible, including 12 separate analyses. The meta-analysis showed that PPI users have an increased risk of developing community-acquired enteric infection (pooled odds ratio [OR] = 4.28; 95% CI = 3.01-6.08). There was significant heterogeneity between the studies ( I 2 = 85%; P < 0.001), which was partly explained by type of microorganism. The strength of the association was similar for Salmonella (pooled OR = 4.84; 95% CI = 2.75-8.54; I 2 = 58.7%; P = 0.064) and Campylobacter (pooled OR = 5.09; 95% CI = 3-8.64; I 2 = 81%; P < 0.001) but lower for studies that combined all bacteria (pooled OR = 2.42; 95% CI = 0.96-6.14; I 2 = 94.3%; P < 0.001). Conclusion: PPI users have an increased risk of developing community-acquired enteric infections compared with nonusers. The heterogeneity was partially explained by type of microorganism; the association is stronger for Salmonella and Campylobacter than for all bacteria combined.Keywords
This publication has 21 references indexed in Scilit:
- Association between Proton Pump Inhibitor Therapy and Clostridium difficile Infection: A Contemporary Systematic Review and Meta-AnalysisPLOS ONE, 2012
- Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infectionAlimentary Pharmacology & Therapeutics, 2011
- Risk factors for indigenousCampylobacter jejuniandCampylobacter coliinfections in The Netherlands: a case-control studyEpidemiology and Infection, 2010
- Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetryJournal of Clinical Epidemiology, 2008
- Use of Acid-Suppressing Drugs and the Risk of Bacterial GastroenteritisClinical Gastroenterology and Hepatology, 2007
- Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infectionsEpidemiology and Infection, 2005
- Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physicianBest Practice & Research Clinical Gastroenterology, 2001
- Gastric Acid, Acid-Suppressing Drugs, and Bacterial GastroenteritisEpidemiology, 1997
- Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study: Table 1BMJ, 1996
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986